Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find PharmaFlow Article for NCGC00024859-05

    Client Email Product

    NCGC00024859-05

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    35
    US DMFs Filed

    US DMFs Filed

    22
    CEP/COS Certifications

    CEP/COS Certifications

    5
    JDMFs Filed

    JDMFs Filed

    8
    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    5
    API REF. PRICE (USD / KG)
    50

    API Market Place

    24
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    71
    Europe

    Europe

    2
    Canada

    Canada

    7
    Australia

    Australia

    0

    South Africa

    South Africa

    25
    Uploaded Dossiers

    Uploaded Dossiers

    22
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    45.00

    Annual Reports

    0

    FDF Market Place

    2
    EXCIPIENTS
    196
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    7
    REF STANDARD

    EDQM

    3

    USP

    1

    JP

    0

    Other Listed Suppliers

    8
    SERVICES

    0

    BlogBlog
    Full View ScreenFull Screen View
    Can Cimetidine, a common antacid, be repurposed for cancer?

    Can Cimetidine, a common antacid, be repurposed for cancer?

    A clinical study published in one of the leading oncology journals, Cancer, shows that Cimetidine can be synergized with other drugs, including existing therapies, and that its potential as an anti-cancer therapeutic should be explored much further. Cimetidine has historically been used to treat indigestion through its ability to block histamine receptors in the gut. A widely available generic, Cimetidine was launched by GlaxoSmithKline under the trade name Tagamet. In some countries, like the USA, the product is available over-the-counter and is used for treating ulcers and heartburn.  The authors in their research share abundant pre-clinical and clinical evidence which demonstrate the therapeutic effects of Cimetidine in a range of cancers, especially cancers of the gastrointestinal tract, renal cell carcinoma and melanoma.  Recycling old drugs makes drug repositioning, or repurposing, an attractive form of drug discovery and accounts for approximately 30% of the newly approved drugs and vaccines by the FDA (US Food and Drug Administration) in recent years.   An enormous source of profits for the pharmaceutical industry and one of the most famous examples of drug repositioning is Viagra. Viagra was originally identified in connection with angina, and was successfully repositioned for erectile dysfunction.  The ReDO project (the repurposing drugs in oncology project), an international global collaboration of researchers, is dedicated to promoting common medicines such as mebendazole (for threadworm infections), nitroglycerin (used to treat angina), itraconazole (broadly used anti-fungal), diclofenac (a commonly prescribed painkiller) and clarithromycin (an antibiotic) as anti-cancer therapies.  The team of researchers combines the expertise of the Anticancer Fund, which is focused on expanding cancer treatment options by repurposing drugs, and Global Cures, a non-profit, medical research organization dedicated to curing patients with cancer.  The authors believe that, should positive results be obtained in an underway clinical trial that is studying the effect of Cimetidine in Colorectal Cancer, the focus on the potential of Cimetidine as an anti-cancer therapeutic will be re-ignited.  Drug Repositioning has been subject to extensive studies over the past few years and there are numerous examples of successful repositioning of products. Success of the ReDO project would allow cheaper access to solutions in the fight against cancer and once again support the case of looking at existing drugs instead of only focusing on novel, and potentially expensive treatments. It indeed brings a lot of hope for cancer patients since many existing treatments carry unwelcome side effects, and so existing drugs whose effects are already well understood and documented may well be utilized to assist treatment without the risk and without the massive cost and side effect implications.  

    Impressions: 2255

    subscribeSubscribe
    ExcelExcel Download

    https://www.pharmacompass.com/radio-compass-blog/can-cimetidine-a-common-antacid-be-repurposed-for-cancer

    #Phispers by PHARMACOMPASS
    12 Mar 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search